Michael Barbella, Managing Editor 01.20.23
Xtremity has closed an $8.1 million Series B3 financing round that added several new investors to the company’s shareholder ranks. The firm plans to use the funds to commercialize its first product, a transtibial prosthetic socket (XtremityTT).
“Xtremity was formed to re-envision prosthetic development and to transform care for individuals living with limb loss or limb difference,” Xtremity President/CEO Maynard Carkhuff said. “With a mission to enhance the patient experience, Xtremity is introducing the first and only socket on the market that enables rapid fabrication and future adjustability; this financing will be crucial in launching XtremityTT and expanding our company.”
